Bernard Huber, CEO and founder of ORYX Translational Medicine, and Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, talk about ORYX's early cancer drug development strategy and partnering models. During BIO-Europe Spring 2016, in Stockholm, Sweden, they discuss how ORYX works with academia, the company's history in early-stage cancer research and the next steps for its three leading therapeutic vaccines.
